- STAT+: Pharmalittle: We’re reading about a Biogen Alzheimer’s drug, skyrocketing 340B drug sales, and moreAn Alzheimer’s drug from Biogen slowed cognitive decline in a mid-stage trial at roughly comparable rates as approved medicinesSTAT · 11d ago↗ source
- What to know about the parasitic diarrhea outbreakFallout from the end of ACA subsidies, the FDA CBER acting director "on planet Earth," and more health news from Morning RoundsSTAT · 11d ago↗ source
- Why Axiom hopes it’s ‘solved 2 major potholes’ that have hurt other stem cell biotechsWhen Axiom's stem cell therapy demonstrated a 0% mortality rate over two years in potentially fatal newborn neurological diseases this week, the biotech's leadership saw a broader validation for th…